Copy number variants CNVs at chromosome 16p Joo Wook AhnSusan BintAnne BergbaumKathy MannRichard P HallThursday, 28 March, The avoidance of twin or higher-order multiple pregnancies is in the best interest of families, medical practitioners and health services, given the health hazards and costs associated with higher-order multiples. Friday, 1 March, Recent publications have indicated that the risk of fetal loss following amniocentesis or chorionic villus sampling is lower than the figure widely quoted in pretest counseling.
Date of revision of the text This information is intended for use by health professionals This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Qualitative and quantitative composition One vial contains mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian Chinese hamster ovary cell suspension culture and purified by several chromatography steps including specific viral inactivation and removal procedures.
For the full list of excipients, see section 6. Pharmaceutical form Powder for concentrate for solution for infusion. White to pale yellow lyophilised powder.
Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
Ontruzant should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay see sections 4. Metastatic gastric cancer Ontruzant in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Accurate and validated assay methods should be used see sections 4. Ontruzant treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy see section 4.
Ontruzant intravenous formulation is not intended for subcutaneous administration and should be administered via an intravenous infusion only.
In order to prevent medication errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Ontruzant trastuzumab and not trastuzumab emtansine. Administration in combination with paclitaxel or docetaxel In the pivotal trials Hg, Mpaclitaxel or docetaxel was administered the day following the first dose of trastuzumab for dose, see the Summary of Product Characteristics SmPC for paclitaxel or docetaxel and immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
Administration in combination with an aromatase inhibitor In the pivotal trial BO trastuzumab and anastrozole were administered from day 1.
There were no restrictions on the relative timing of trastuzumab and anastrozole at administration for dose, see the SmPC for anastrozole or other aromatase inhibitors.
Patients with EBC should be treated with Ontruzant for 1 year or until disease recurrence, whichever occurs first; extending treatment in EBC beyond one year is not recommended see section 5. Dose reduction No reductions in the dose of trastuzumab were made during clinical trials.
Patients may continue therapy during periods of reversible, chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time.
Refer to the SmPC for paclitaxel, docetaxel or aromatase inhibitor for information on dose reduction or delays.Cookie Information. We are using cookies on this website. We assume your consent, as you are making use of this website.
A cookie is a simple small file sent with the pages of this website and stored by your browser on the hard disk of your computer. One vial contains mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange chromatography including specific viral inactivation and removal procedures.
This Childhood Cancer Genomics summary provides a brief synopsis of current knowledge about the genomic landscape of specific childhood cancers.
Get detailed information about various genetic alterations and precision medicine concepts in childhood cancers in this summary for clinicians. HER2 testing is mandatory prior to initiation of therapy (see sections and ). Ontruzant treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy (see section ), and should be administered by a healthcare professional only.
Apr 23, · Fluorescence In Situ Hybridization (FISH) Review Introduction to Fluorescence Microscopy (Nico Stuurman) ACD RNAscope® in situ Hybridization (ISH) Technology Overview - Duration.
Fluorescence in situ Hybridization Hardware and Software Implications in the Research Laboratory Nearly a quarter-century has passed since the first research articles introducing in situ hybridization as a method of detecting and studying DNA sequences in chromosomes and cells appeared in the literature.